The clinical course of prostate cancer (PCa) is highly variable, demanding an individualized 25 approach to therapy and robust prognostic markers for treatment decisions. We present a 26 random forest-based classification model to predict aggressive behaviour of PCa. DNA 27 methylation changes between PCa cases with good or poor prognosis (discovery cohort with 28 n=70) were used as input. The model was validated with data from two large independent 29
Introduction 40
Prostate cancer (PCa) is the second most prevailing cancer in the male population 41 worldwide, with an estimated 1.1 Mio. newly diagnosed cases and 307.500 cancer-related 42 deaths in 2012 (Ferlay et al, 2015; Stewart & Wild, 2014) . Although the aetiology of PCa is 43 controversial, it is likely to result from accumulating DNA damage in stress-exposed ageing 44 prostate epithelial cells (Gelmann, 2008) . Specifically, chromosomal rearrangements and 45 oncogene fusion genes in these cells are driven by androgens (Weischenfeldt et al, 2013) . 46
Despite a large number of studies that have suggested a multitude of candidate prognostic 47 markers in PCa (Schlomm et al, 2007) , none of these genes has proven to be superior over 48 the established histological prognostic factors including tumour stage and Gleason grade. 49
Localized PCa with low Gleason score usually remains indolent, requiring only active 50 surveillance or minimal treatment. Nevertheless, many patients may be over-treated with 51 associated side effects and substantial costs (Cooperberg et al, 2011) . There is, therefore, 52 general agreement that novel specific biomarkers for the diagnosis and prognosis of PCa are 53 needed for an efficient clinical management of this disease (Prensner et al, 2012) . 54
Recent high-resolution genome-wide studies have significantly improved our understanding 55 of chromosomal and genetic alterations associated with PCa development, such as the 56 androgen-driven formation of gene fusions between the transmembrane serine protease 57 TMPRSS2 and a member of the oncogenic ETS transcription factor family like ERG in about 58 50% of all PCa cases, and frequent loss of the tumour suppressor gene PTEN (Cancer 59 Genome Atlas Research, 2015; Fraser et al, 2017; Gerhauser et al, 2018; Taylor et al, 2010; 60 Tomlins et al, 2005; Weischenfeldt et al, 2013) . These events affect signalling pathways and 61 lead to alterations in gene expression programs that have been used for the development of 62 gene signatures (genomic classifiers) as biomarkers for the prediction of PCa prognosis. 63
Although several studies have demonstrated some prognostic value of gene expression-64 based signatures, due to the limited stability of RNA and often low quality when extracted 65 from formalin-fixed paraffin-embedded (FFPE) material, protein-or DNA-based methods 66 might be superior to RNA expression profiles for biomarker development. 67
There is substantial evidence that genetic defects in PCa are complemented or even 68 preceded by epigenetic aberrations such as DNA methylation (Florl et al, 2004; Nelson et al, 69 2009 ). Methylation of CpG rich sequences in gene promoter regions increases with 70 increasing stage of malignancy in various human cancers and often results in gene silencing 71 (Jones, 2012) . On the other hand, loss of methylation can be predictive of increased gene 72 expression (Weigel et al, 2016) . Novel technologies based on genome-wide screens for 73 aberrant DNA methylation and epigenetic gene silencing, including the widely used Illumina 74 450k Beadchip arrays, have allowed identification of hundreds of genes aberrantly 75 methylated during prostate cancer development (Borno et al, 2012; Brocks et al, 2014; 76 Cancer Genome Atlas Research, 2015; Fraser et al, 2017; Kim et al, 2011; Kobayashi et al, 77 2011; Kron et al, 2009; Weischenfeldt et al, 2013) . These cancer-specific epigenetic 78 alterations have been shown to enable the development of methylation-based assays to 79 distinguish between benign and malignant tissue and to predict the course of the disease 80 (Haldrup et al, 2013; Jeronimo et al, 2011; Nelson et al, 2009; Yang & Park, 2012) . 81
In recent years, machine-learning techniques became widely used in modern molecular 82 research to build predictive models (Camacho et al, 2018) . Random forest (Breiman, 2001) is 83 an ensemble learning method based on the construction of many classification trees. Main 84 benefits of the method are its robustness against overfitting, user-friendliness and the easy 85 interpretation of the model (Breiman, 2001 for at least 5 years) or poor prognosis (systemic presence of metastatic disease, indicated by 97 biochemical prostate-specific antigen (PSA)-based recurrence (BCR) within 3 years and no 98 response to local radiation therapy) for genome-wide methylation analyses using Illumina 99 450k arrays. The two groups showed differences in preoperative PSA levels (p=1.2*10 -6
). As 100 a result of the selection criteria, the two sample groups are very different regarding their 101 7 PRAD cohort (n=477 , Table 2 ), we observed an AUC of 68.7% and an error rate of 43% 146 ( Figure 3E) . With a preselected subset (n=84 , Table 2 ), we achieved an AUC of 77.5% and 147 an error rate of 28.6%. Our classifier stratified both validation cohorts according to PSA 148 recurrence-free survival (log-rank p-value <0.0001 for both cohorts) ( Figure 3D and F, and 149
Supplementary Figure 3) . In the ICGC dataset, our model proved to be an independent 150 predictor of recurrence-free survival, when the Gleason score was included in the model 151 (Cox regression p=0.011). 152
Candidate selection
153
The relevance of the DMS included in the model is supported by previous literature. They are 154 often located in promoter or enhancer regions of genes of importance for the aggressiveness 155 or progression of prostate cancer. Based on their localization in regulatory regions and 156 distance from transcription start sites (TSSs), DMS were associated to genes. The genes 157 were ranked to select the top10 candidates for confirmatory analyses based on 158 immunohistochemistry (IHC), as further described below (Table 3, with individual Kaplan-159 Meier curves for the candidate gene-related CpG sites and the full model in Supplementary 160
Figure 2). 161
Among the top candidate DMS, five sites affected the promoter region of zinc-finger proteins. 162
Four sites were located in the promoter of ZFP36L2 (cg16876647, cg12092201, 163 cg11462315, cg08738430), while a poised promoter of ZIC2 was affected by one CpG site 164 (cg24690071). ZFP36L2 encodes a CCH-type zinc finger protein, which is regulated by the 165 cell-cycle, might play a role in DNA damage response (Noguchi et al, 2018) , and inhibits cell 166 proliferation Suk et al, 2018) . In PCa, ZFP36L2 upregulation was associated 167 with the transcription factor Runx2 and poor prognosis (Baniwal et al, 2010) . ZIC2 belongs to 168 a family of transcription factors involved in neuro-ectodermal development. Elevated ZIC2 169 mRNA expression was described in high Gleason prostate cancer (Hoogland et al, 2016) . 170
Cg05131488 and cg21940313 are located in the enhancer and promoter regions of ETV1 171 and ETV4. These are both members of the erythroblast transformation-specific (ETS) 172 transcription factor family along with ERG and commonly affected by gene fusions in PCa8 (Tomlins et al, 2006; Tomlins et al, 2005) . Their overexpression showed oncogenic effects 174 with slightly overlapping functions (Mesquita et al, 2015) . 175
Cg04211581 is located only 26 bps from the TSS of ESR1. ESR1 encodes estrogen receptor 176 alpha (ERα), the role of which was proposed in PCA, however, is still controversial (Yeh et al, 177 2014) . 178 TBX2 and TBX4 came up as candidate genes, since cg12658720 lies in an enhancer region 179 between them. As members of the T-box (TBX) protein family, TBX proteins, mainly TBX2 180 and TBX3 play important oncogenic role in several types of cancer (Chang et al, 2016) . 181
Platelet-derived growth factor (PDGF) acts as an oncogene promoting tumor growth and 182 survival in prostate cancer, as well as in other cancer types. It is commonly overexpressed in 183 prostate cancer, therefore represents a potential therapeutic target (Heldin, 2013) . 184
A highly predictive CpG site, cg07043604, is located in an enhancer region around 130kb 185 away from PRKDC, which encodes the catalytic subunit of DNA-dependent protein kinase 186 (DNA-PKcs). Previous research identified DNA-PKcs as a master regulator of pro-metastatic 187 signaling and showed that its expression is strongly correlated with survival (Goodwin et al, 188 2015 and was absent in majority of the tumours (76.7%) ( Figure 4A , Table 4 In the present study we have identified methylation differences related to PCa prognosis, and 214 subsequently showed that methylation-based prediction of PCa prognosis using random 215 forest-based modelling is feasible with high accuracy. 216
PCa is the most prevalent cancer among men in Germany. The 5-year survival rate is 91% 217 (German Cancer Registry), since in many cases the cancer remains indolent, with no need of 218 aggressive treatment. However, some patients develop an aggressive from of the disease. 219 Therefore, biomarkers predicting the prognosis of PCa are needed for an efficient clinical 220 management of this disease (Prensner et al, 2012) . 221 DNA methylation is an excellent source for biomarker development, since it is a stable 222 modification and can be quantitatively determined in clinical samples with high throughput 223 and precision and relatively low cost (Claus et al, 2012) . Previous studies trying to establish 224 a methylation-based classifier for prostate cancer mostly used a preselected set of genes 225 (Ahmad et al, 2016; Litovkin et al, 2015) , or used high Gleason score as an outcome (Bhasinet al, 2015; Geybels et al, 2016 ). Here we are presenting a genome-wide approach, with 227 PSA recurrence-free survival as an endpoint, to achieve the strongest relevance for clinical 228 decisions. One limitation of our study is the use of the Illumina 450k platform for biomarker 229 selection, which limits methylation analyses to preselected CpG sites on the 450k array 230 (enriched for CpG islands and flanking regions, bioinformatically predicted enhancers, 231
DNase I hypersensitive sites, and validated differentially methylated regions (Stirzaker et al, 232 2014) ). Future studies using whole genome bisulfite sequencing (WGBS) of all >29 Mio CpG 233 sites in the human genome will allow identification of additional biomarkers. 234
Our discovery cohort consisted of 70 patients, 35 with good and 35 with bad prognosis. After 235 cell type adjustments, our cut-off criteria for selection of differentially methylated CpG sites 236 were mean beta difference > 0.1 and an FDR-adjusted p-value < 0.2. Altogether, 402 DMS 237 and the PEPCI score for tumour aggressiveness (Gerhauser et al, 2018) were included in the 238 prediction model. Our random forest-based model showed good performance with the 239 discovery cohort. We were able to validate our results using the ICGC PCa cohort of early 240 and late prostate cancer (AUC 77.1%), with slightly worse performance using the TCGA 241 PRAD dataset (AUC 68.7%). Different reasons might contribute to the lower performance 242 with the TCGA-PRAD cohort, such as possibly different definitions of PSA recurrence-free 243 survival, and the generally high Gleason score and high tumor stage of the TCGA patients. 244
Other genome-wide studies have faced similar problems using TCGA as a validation set 245 (Bhasin et al, 2015; Mundbjerg et al, 2017) . Nevertheless, for both ICGC and TCGA 246 validation cohorts, the resulting prognostic subgroups had highly significantly different 247 survival rates. 248 A recent proteomics-based biomarker study of curable prostate cancer reported a stronger 249 link of DNA methylation status to protein than mRNA abundance (Sinha et al, 2019) . In line 250 with these findings, we performed a validation of the clinical impact of ZIC2 as one of the 251 candidate genes on more than 12000 micro-arrayed PCa cases. The zinc finger of the 252 cerebellum (ZIC) family of genes consists of five human homologues ZIC1-5 (Ali et al, 2012) . 253 ZIC family members inhibit TCF4/β-Catenin and interact with GLI signalling (Ishiguro et al, 254 2018) . In addition, an oncogenic role of ZIC family members has been reported. ZIC1, −2 255 and −5 are over-expressed in meningioma, while ZIC4 is over-expressed in 256 medulloblastomas (Aruga et al, 2010) . Methylation of ZIC4 in bladder cancer is predictive for 257 progression (Beukers et al, 2015) . Promoter methylation of ZIC1 is associated with gastric 258 cancer (Schneider et al, 2013; Wang et al, 2009) . ZIC2 is related to the sonic hedgehog 259 pathway. Its oncogenic role was described in epithelial ovarian cancer (Marchini et al, 2012) , 260 hepatocellular carcinoma (Lu et al, 2017) and pancreatic cancer (Inaguma et al, 2015) . High 261 expression of ZIC2 was associated with survival in oral squamous carcinoma (Sakuma et al, 262 2010 In order to build a classifier that predicts the patients' outcome the best, a highly selected 278 group of patients was included in the study. Sample selection was based on the following 279 criteria: good prognosis indicated by presence of organ confined disease (pT2) and lack of The ICGC PCa cohort has been described earlier (Gerhauser et al, 2018) . Clinical 296 information for the TCGA-PRAD cohort was downloaded from cBioPortal in June 2018 297 (Table 2) . For the subcohorts, patients were selected as good prognosis patients by lack of 298 BCR within 5 years and a disease stage pT2, and as poor prognosis patients when suffering 299 from BCR within 3 years and having a stage pT3 or pT4. 300 DNA methylation processing 301 DNA methylation was assessed using Illumina HumanMethylation450 Array. The methylation 302 data was processed using the RnBeads R package . Probes with SNPs 303 (dbSNP 144) overlapping with the C nucleotide of the CG site and having MAF>0.01 (28722 304 probes) were excluded. Probes with high likelihood of false hybridization (28736 probes, as 305 defined in RnBeads) were also removed. Quality filtering was performed using the Greedycut 306 algorithm, which removed 21040 probes and 11 samples. Additional 969 non-CpG probesand 9229 probes located on the sex chromosomes were removed. No normalization or 308 background correction was used. Methylation data for the discovery cohort has been 309 uploaded to GEO under accession No. GSE127985. 310 During the analysis, a batch effect was observed between data from fresh frozen (TCGA 311 PRAD and ICGC PCa cohort) and formalin-fixed tissue (discovery cohort). In order to have a 312 generalizable model, we avoided shifting the beta values as would happen with batch 313 correction methods. Instead, we used principal component analysis (PCA) on the top 10000 314 most variable CpG sites to identify the probes affected by this effect. This was done using 315 two independent datasets containing formalin-fixed (Brocks et al, 2014) or fresh frozen tissue 316 (Fraser et al, 2017) , and removed the top 5000 sites captured by PC2, the main principal 317 component affected by the sample type. The PEPCI score and the basal, stromal, luminal, T-318 luminal and immune cell composition were estimated using the PEPCI R package 319 (Gerhauser et al, 2018) . Linear models of the limma package (Ritchie et al, 2015) were 320 applied to identify differentially methylated probes after adjustments for age, basal, stromal 321 and immune cell content. CpG sites with FDR-adjusted p-values < 0.2 and mean methylation 322 difference > 0.1 (10%) were used to build the model. Enrichment analysis of the significantly 323 methylated sites, promoters and genes were performed with EpiAnnotator (Pageaud et al, 324 2018) . Annotation of the most important CpG sites of the random forest model was done 325 using the GREAT tool (McLean et al, 2010) . 326
Random forest classifier 327 A Random forest-based classifier was built using the randomForest R package, which is 328 based on the algorithm of Breiman and Cutler (Breiman, 2001 ). Random forest is a learning 329 method that constructs numerous decision trees and outputs the classes (in case of 330 classification) of the individual trees. The predicted class of the input instance will be decided 331 upon majority vote. The schematic principle of the random forest can be seen in 332
Supplementary Figure 4. 333
The random forest uses out-of-bag (OOB) error to measure the performance of the model on 334 the training set. In a nutshell, during the algorithm, each tree is built on a bootstrap training 335 set, which is selected from the discovery cohort with replacement. The bootstrap training set 336 is about two-thirds of the discovery cohort. Classification of the instances left out (OOB 337 samples) is used to estimate a generalization error (called OOB error). The OOB error will 338
give an unbiased estimate of the current classification error, while the bagging method will 339 decrease the chance of overfitting. 340
Two variable importance scores are used in random forest. The mean decrease in accuracy 341 reflects a variable importance measure to assess the prediction strength of each predictor 342 variable. When a tree is grown, the OOB samples are used to calculate the error rate. Then, 343 the values of a given predictor variable are randomly permuted and the error rate is 344 calculated again. The decrease in accuracy caused by the permutation is averaged over all 345 trees. The mean decrease in Gini score gives the improvement in the split-criterion at each 346 split in each tree (Hastie et al, 2009) . 347
Twenty different models were trained as follows: data was randomly split into training (80%) 348 and test (20%) set. The model was trained on the training set, with 10000 trees and 19 349 variables to select randomly for each tree. Prediction accuracy was measured on the test set. 350
The results were collected and the best performing model was selected. This model was 351 then optimized for the number of variables selected for each tree. For variable selection, 352
CpG sites were ranked based on mean decrease in accuracy and mean decrease in Gini 353 scores (Hastie et al, 2009) . 354
Validation of the classifier was performed using the TCGA-PRAD and the ICGC PCa cohort 355 of early and late prostate cancer and evaluated with ROC curve analysis, using the ROCR R 356 package (Sing et al, 2005 First, we used the GREAT tool and the gene annotation of the Illumina 450k methylation 363 array to identify the possible gene-CpG site associations, by selecting the genes closest to 364 the sites. The CpG sites in close vicinity to genes (± 2 kb) were selected, while among the 365 sites further away from genes, sites were included if they were located in enhancer regions 366 based on ChromHMM data of PrEC prostate epithelial cells and the PC3 prostate cancer cell 367 line (Taberlay et al, 2014 Table 3 ). All prostate 373 specimens were analysed according to a standard procedure, including complete embedding 374 of the entire prostate for histological analysis (Schlomm et al, 2008) . Histo-pathological data 375 was retrieved from the patient files, including tumour stage, Gleason grade, nodal stage and 376 resection margin status. Follow-up data were available for a total of 14464 patients with a 377 median follow-up of 48 months (range: 1 to 241 months; Supplementary Table 3) . PSA 378 values were measured in regular intervals following surgery and PSA recurrence was defined 379 as the measurement of a postoperative PSA of ≥0.2 ng/ml and increasing. The TMA 380 manufacturing process was described earlier in detail (Kononen et al, 1998) . In short, one 381 0.6 mm core was taken from a tumour-containing tissue block from each patient. The 382 molecular database attached to this TMA contained results on ERG expression in 10711 383 (Weischenfeldt et al, 2013) , ERG break apart FISH analysis in 7122 (expanded from (Minner 384 et al, 2011) ), deletion status of 5q21 (CHD1) in 7932 (expanded from (Burkhardt et al, 385 2013)), 6q15 (MAP3K7) in 6069 (expanded from ), 10q23 (PTEN) in 6704 386 (expanded from (Krohn et al, 2012) ) and 3p13 (FOXP1) in 7081 (expanded from (Krohn et al, 387 2013)) cancers. 388
Immunohistochemistry. Freshly cut TMA sections were immunostained on one day and in 389 one experiment. Slides were deparaffinised and exposed to heat-induced antigen retrieval for 390 5 minutes in an autoclave at 121 °C in pH 7.8 Tris-EDTA-Citrate buffer. Primary antibody 391 specific for ZIC2 (antibodies online, ABIN2776475) was applied at 37 °C for 60 minutes. 392
Bound antibody was then visualized using the EnVision Kit (Dako, Glostrup, Denmark) 393 according to the manufacturer´s directions. ZIC2 staining intensity was assessed as negative 394 or positive. 395
Statistics. Statistical calculations were performed with JPM 12 software (SAS Institute Inc., 396 NC, USA). Contingency tables and the chi²-test were performed to search for associations 397 between molecular parameters and tumour phenotype. Survival curves were calculated 398 according to Kaplan-Meier. The log-rank test was applied to detect significant survival 399 differences between groups. Cox proportional hazards regression analysis was performed to 400 test the statistical independence and significance between pathological, molecular and 401 clinical variables. Separate multivariate analyses were performed using different sets of 402 parameters available either before or after prostatectomy. a Good prognosis defined as an organ confined disease (pT2) and lack of biochemical (PSA based) recurrence (BCR) for at least 5 years. Bad prognosis defined as systemic presence of metastatic disease, indicated by recurrence within 3 years and no response to local radiation therapy. 
